#1 Clinical Trials Search in Europe

ANGIOTENSIN II

Clinical trials are studying ANGIOTENSIN II in different patient groups, including adults after cardiac surgery, people with liver cancer, and children with life-threatening low blood pressure. These studies look at safety and how well the treatment works in each setting.

Table of contents

Trial overview

The data include three interventional studies of ANGIOTENSIN II, each looking at a different clinical problem: kidney injury after heart surgery, liver cancer treatment, and severe low blood pressure in children.[1][2][3]

All three studies are marked Authorised, which means they have been approved to move forward in the study process.[1][2][3]

Acute kidney injury study after cardiac surgery

Trial NCT06615102 is studying whether ANGIOTENSIN II can reduce the occurrence of acute kidney injury after cardiac surgery.[1] The trial compares ANGIOTENSIN II with norepinephrine, another blood pressure medicine, in people after heart surgery.[1]

The main outcome is the rate of AKI KDIGO stage 2 or 3, or death, within 72 hours after surgery.[1] KDIGO is a kidney injury staging system; stage 2 or 3 means a more serious level of kidney injury.[1]

This study is large, with an enrollment of 1022 people, and it is listed as Low Intervention in the source data.[1]

Liver cancer radioembolization study

Trial 2025-521870-33-00 is called the RADIANT study and is testing ANGIOTENSIN II in people with primary or secondary liver cancer.[2] The study looks at whether ANGIOTENSIN II can make radioembolization more effective.[2]

Radioembolization is a cancer treatment that delivers tiny radioactive microspheres into the blood supply of the tumor.[2] In this study, the main measure is the tumor-to-non-tumor ratio, which compares how much treatment reaches the tumor versus nearby normal tissue.[2]

The trial uses imaging tests called 90Y PET/CT and 99mTc-MAA SPECT/CT to compare results with and without ANGIOTENSIN II.[2] It is a small Phase 2 study with 15 participants.[2]

Pediatric shock and low blood pressure study

Trial 2025-523750-14-00 is studying ANGIOTENSIN II in patients 0 to 17 years old who have refractory hypotension in distributive shock.[3] Refractory hypotension means blood pressure that stays too low even after usual treatment.[3]

The study compares ANGIOTENSIN II with placebo while children receive fluids and standard-of-care vasopressors.[3] A placebo is a treatment with no active medicine, used here to help compare results fairly.[3]

The main outcome is the change in the dose of standard blood pressure medicines, measured as norepinephrine base equivalent dose, during the first 6 hours of treatment.[3] This Phase 3 trial includes 143 participants.[3]

Main outcomes and what they mean

The kidney study focuses on whether serious kidney injury or death happens within 72 hours after cardiac surgery.[1]

The liver cancer study focuses on whether ANGIOTENSIN II improves the tumor-to-non-tumor ratio after treatment, which may show better targeting of the tumor area.[2]

The pediatric shock study focuses on whether ANGIOTENSIN II can reduce the amount of standard blood pressure medicine needed in the first 6 hours.[3]

Who the trials are for

These studies are not for one single disease group; they are designed for very different patients.[1][2][3]

  • The first study is for people after cardiac surgery who are at risk of acute kidney injury.[1]

  • The second study is for people with primary or secondary liver cancer.[2]

  • The third study is for children and teenagers from 0 to 17 years old with refractory hypotension in distributive shock.[3]

Study phases and current status

The source data show one Phase 2 study, one Phase 3 study, and one study labeled Low Intervention.[1][2][3]

Phase 2 studies usually look more closely at whether a treatment seems to work and how it performs in a smaller group, while Phase 3 studies compare treatments in larger groups to confirm results.[2][3]

All three studies are marked Authorised, and their enrollment ranges from 15 to 1022 participants.[1][2][3]

Trial ID Phase Condition studied Status Enrollment
NCT06615102 Low Intervention Acute kidney injury after cardiac surgery Authorised 1022
2025-521870-33-00 Phase 2 Liver cancer (primary or secondary) Authorised 15
2025-523750-14-00 Phase 3 Refractory hypotension in distributive shock Authorised 143

FAQ

  • What are the ANGIOTENSIN II trials studying? The trials are studying whether ANGIOTENSIN II can help lower the risk of acute kidney injury, improve liver cancer radioembolization results, and reduce the need for standard blood pressure medicines in children with severe shock.
  • Who can take part in these studies? The studies target different groups: people after cardiac surgery, patients with primary or secondary liver cancer, and children ages 0–17 with refractory hypotension in distributive shock.
  • What phases are the ANGIOTENSIN II trials? The data include one Phase 2 study, one Phase 3 study, and one trial listed as Low Intervention. This shows the research is at different stages of testing.
  • What outcomes are being measured? The trials measure outcomes such as moderate or severe acute kidney injury or death within 72 hours, tumor-to-non-tumor ratio improvement, and changes in vasopressor dose over the first 6 hours.
  • Are these trials already open? All three trials in the data are marked Authorised. That means they have been approved to begin or are allowed to proceed.

Ongoing Clinical Trials on ANGIOTENSIN II

  • Study of intra-arterial angiotensin II during radioembolization to improve treatment effectiveness in patients with primary or secondary liver cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Reducing Acute Kidney Injury After Heart Surgery Using Angiotensin II or Noradrenaline for Patients with Low Blood Pressure

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Angiotensin II in Children and Adolescents With Refractory Hypotension in Distributive Shock

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

Glossary

  • Acute kidney injury: A sudden loss of kidney function. In the trial, researchers are checking whether ANGIOTENSIN II can reduce moderate or severe cases after cardiac surgery.
  • Cardiac surgery: An operation on the heart. One trial studies patients after this type of surgery.
  • Distributive shock: A serious condition where blood vessels do not keep enough pressure to support blood flow to organs.
  • Refractory hypotension: Very low blood pressure that does not improve easily with usual treatment.
  • Vasopressors: Medicines used to raise blood pressure.
  • Standard-of-care (SOC): The usual treatment that doctors normally give for a condition.
  • Norepinephrine base equivalent dose (NED): A way to measure the total amount of blood pressure medicine a patient needs, converted into one common unit.
  • Radioembolization: A cancer treatment that sends tiny radioactive particles into the blood supply of a tumor.
  • Tumor-to-non-tumor ratio (TNR): A measurement that compares how much treatment reaches the tumor compared with nearby normal tissue.
  • PET/CT: A scan that combines two imaging methods to show where treatment or disease is in the body.

References